Skip To Main Content
Lisle Kingery on Muck Rack

Lisle Kingery

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lisle

Contact Lisle, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

XPro1595 in early Alzheimer’s disease with inflammation: results from the phase 2 MINDFuL trial

|
By Judith Jaeger, Kim A Staats, Sarah Smith Barnum, Sharon Cohen, Malú Gámez Tansey, Raymond J. Tesi, Christopher Barnum, Parris Pope, Lisle Kingery, Melanie Buitendyk
| Nature Verified
Abstract Alzheimer’s disease (AD) involves chronic neuroinflammation driven by tumor necrosis factor (TNF). XPro1595 selectively neutralizes pathological soluble TNF while preserving neuroprotective transmembrane TNF signaling. MINDFuL (clinicaltrials.gov NCT05318976, registration April 1st 2022) was a Phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study.
Open in Who Shared Issue with article?
See all 1 articles